NCT07656116招募中1 期
A Phase I Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2026年1月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 1
研究概览
简要总结
To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.
详细描述
This is an open-label, dose-escalation phase I clinical trial designed to evaluate the safety and tolerability of combined administration of vesicular stomatitis virus (VSV) injection solutions carrying different targets via multiple routes in patients with advanced malignant solid tumors, and to preliminarily explore the maximum tolerated dose (MTD), recommended phase II dose (RP2D), as well as the preliminary anti-tumor activity and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of this regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily sign the informed consent form, understand this study, and agree to comply with the protocol and complete all trial procedures
- •Be at least 18 years of age at the time of signing the ICF, with no gender restrictions.
- •Patients with advanced solid tumors confirmed by histopathological/cytological examination of primary and/or metastatic lesions.
- •Patients who have failed standard therapy, lack a standard last-line treatment option, or are medically ineligible for standard therapy.
- •Subjects with an ECOG performance status of 0-2 and an estimated survival of ≥12 weeks.
- •Adequate organ and hematopoietic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/LPlatelet count ≥ 75 × 10⁹/L (no platelet transfusion or thrombopoietin (TPO) therapy within 2 weeks prior to first dose)Hemoglobin ≥ 90 g/L (no blood transfusion within 2 weeks)Serum creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine clearance (CCr) ≥ 50 mL/min Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 × ULN for patients with liver metastases, AST and ALT < 5 × ULN， Serum total bilirubin (TBIL) ≤ 2 × ULN， International Normalized Ratio (INR) ≤ 1.5 × ULN, or activated partial thromboplastin time (APTT) ≤ 1.5 × ULN
- •Women of childbearing potential must have a negative pregnancy test within 7 days prior to treatment initiation.
- •Male and female subjects of reproductive potential must agree to use reliable contraception during the trial and for at least 6 months after the last dose. Translated with DeepL.com (free version)
排除标准
- •Subjects with other active malignancies within the past 5 years. Exceptions include subjects who have achieved complete remission and require no follow-up treatment, and subjects with malignancies within the scope of the indication.
- •Lesions intended for injection with a maximum diameter >100 mm；
- •Subjects who have participated in or are currently participating in other drug or medical device clinical trials within the past 4 weeks；
- •Subjects scheduled for or who have previously undergone tissue/organ transplantation；
- •Subjects with Human Immunodeficiency Virus (HIV) infection who have experienced AIDS-related opportunistic infections within the past 12 months, or who have a CD4+ T-cell (CD4+) count < 350 cells/uL Patients with positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening, with HBV-DNA above the lower limit of detection patients with positive HCV antibody at screening and HCV-RNA above the lower limit of detection subjects with positive syphilis serology
- •Subjects requiring antiviral medication during the study period or within 5 half-lives of antiviral medication at the time of first dosing.
- •Subjects requiring therapeutic anticoagulant medication during the study period.
- •Subjects with uncontrolled active infection of ≥Grade 3 severity according to CTCAE v5.0 that is clinically significant
- •Received antineoplastic therapy (chemotherapy, radiotherapy, biologic therapy, endocrine therapy, immunotherapy, etc.) within 4 weeks prior to first dose Received small-molecule targeted therapy or oral fluorouracil-based agents within 2 weeks prior to first dose or within 5 half-lives (whichever is longer) Received Chinese herbal medicine or proprietary Chinese medicine with antitumor indications within 2 weeks prior to first dose Received Chinese herbal medicine or proprietary Chinese medicine with antitumor indications within 2 weeks prior to first dose Received nitrosourea or mitomycin C within 6 weeks prior to first dose Palliative radiotherapy for non-target lesions is permitted (≥2 weeks prior to first dose)
- •Uncontrolled hypertension, pulmonary hypertension, or unstable angina myocardial infarction, coronary artery bypass grafting, or stenting within 6 months prior to dosing history of chronic heart failure at New York Heart Association (NYHA) functional class III-IV Severe arrhythmias requiring treatment (excluding atrial fibrillation or paroxysmal supraventricular tachycardia deemed by the investigator to have no impact on the trial), including QTcF ≥ 450 ms in males or ≥ 470 ms in females (calculated using Fridericia's formula) cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months prior to enrollment
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A Phase 1/2 Study of the Safety and Tolerability of ICM VTx-002 in participants with ALSAmyotrophic Lateral Sclerosis2025-522697-37-00VectorY Therapeutics B.V.4
尚未招募
3 期
A Study to Compare the Efficacy, Safety, Immunogenicity and Pharmacokinetics of Biosimilar Vedolizumab Injection in Patients with Moderate to Severe Active Ulcerative ColitisCTRI/2025/02/080437Intas Pharmaceuticals Limited214
招募中
3 期
Second Dose of Varicella Vaccine in Healthy ChildrenNCT07475000Sinovac (Dalian) Vaccine Technology Co., Ltd.300
尚未招募
1 期
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young AdultsEBVNCT07557602Vaccine Company, Inc.45
尚未招募
2 期
A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT07522476Virogin Biotech Ltd.30